Hoffman Shifts Focus to AI Drug Discovery
Reid Hoffman, a prominent tech investor and co-founder of LinkedIn, has stepped down from Microsoft's board of directors. After a decade of service, Hoffman is moving into "founder mode" with his latest AI startup, Manus, a drug discovery company. This move signals a renewed focus on early-stage company building for the venture capitalist.
A Profitable Decade at Microsoft
Hoffman joined Microsoft's board in 2016 following the tech giant's $26.2 billion acquisition of LinkedIn. His tenure saw significant strategic moves by Microsoft in the AI space. He was on the board when Microsoft made its initial $1 billion investment in OpenAI in 2019.
Key AI Investments and Departures
Beyond Microsoft, Hoffman was an original investor in OpenAI and served on its board until 2023. He cited potential conflicts of interest as his reason for leaving the OpenAI board. Additionally, Hoffman was part of Microsoft's board during its $650 million "acqui-hire" deal for his AI startup Inflection AI, which brought co-founder Mustafa Suleyman to Microsoft.
Manus: Pioneering "Move 37 AI"
Manus, Hoffman's current focus, is an AI startup dedicated to drug discovery. The company successfully raised over $50 million through seed rounds last year. Hoffman serves as a co-founder and chairman of the board, while Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning physician and biologist, leads as CEO.
- Manus is an AI drug discovery company.
- It secured over $50 million in seed funding.
- Hoffman is a co-founder and chairman.
- General Catalyst is also an investor.
- Dr. Siddhartha Mukherjee is the CEO.
- Mukherjee authored "The Emperor of All Maladies."
- Manus aims for "Move 37 AI" in chemistry.
"One of the things I realized over the last month was that, we're seeing such progress with Manus. I need to get back to founder mode." — Reid Hoffman, Co-founder and Chairman, Manus
Hoffman expressed excitement about dedicating more attention to Manus. He believes the startup is making significant strides with "Move 37 AI," which refers to artificial intelligence that surpasses human creativity in chemistry, particularly in developing treatments for various cancers.
Key Points
- Reid Hoffman departed Microsoft's board after a decade.
- He will focus on his AI drug discovery startup, Manus.
- Manus raised over $50 million in seed funding.
- Hoffman is Manus's co-founder and chairman.
- Dr. Siddhartha Mukherjee serves as Manus CEO.
The Bottom Line
Reid Hoffman's pivot from a corporate board role to a hands-on startup position highlights the intense focus on AI innovation. His commitment to Manus underscores the growing potential of AI in drug discovery. This move signals a significant personal and professional shift for one of tech's most influential figures, potentially accelerating breakthroughs in cancer treatment.